[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"bone-tumor\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:bone-tumor":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,44,71,102,128,154,176,193,220],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":16,"targetDuration":4,"studyType":19,"phases":20,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100632525","integration-of-adaptive-proton-therapy-in-pediatric-solid-tumors-and-hodgkins-lymphoma-100632525",false,"NCT07514819","Integration of Adaptive Proton Therapy in Pediatric Solid Tumors and Hodgkin's Lymphoma","Inclusion Criteria:\n\n* Participants diagnosed with solid tumors, including Rhabdomyosarcoma, Osteosarcoma, Ewing sarcoma, other sarcomas and carcinomas or also Hodgkin's lymphoma.\n* Participants who receive proton radiation therapy at St. Jude Children's Research Hospital.\n* Research participant or legal guardian\u002Frepresentative gives written informed consent.\n\nExclusion Criteria:\n\n* Participants who are not diagnosed with solid tumors or Hodgkin's lymphoma.\n* Participants who are diagnosed with Wilm's tumor or neuroblastoma\n* Participants who do not undergo proton therapy.\n* Participants who are prescribed equal or less than 5 fractions of proton therapy.\n* Participants with severe comorbid conditions that may impact imaging feasibility.\n* Inability to obtain written consent from research participant or legal guardian\u002Frepresentative.\n* Females of child-bearing potential cannot be pregnant or breast-feeding. Female participants \\>10 years of age or post-menarchal must have a negative serum or urine pregnancy test\n\nAll participants receiving proton therapy at St. Jude Children's Research Hospital will be screened for participation on this research protocol based on the Inclusion Criteria and the Exclusion Criteria. Qualified candidates will be selected during the consultation.","ALL",{"count":17,"type":18},100,"ESTIMATED","INTERVENTIONAL",[21],"NA","Pediatric patients receiving proton therapy for solid tumors or Hodgkin's lymphoma may experience anatomical changes during treatment that can affect proton therapy accuracy. This prospective single-arm study uses regular low-dose imaging to monitor these changes and adjust treatment plans as needed. Participants will receive weekly or every-other-week CT scans, with MRI when appropriate, to assess whether the original plan remains accurate. Treatment plans will be updated if tumor coverage decreases by more than 5% or if radiation dose to normal tissues increases by more than 10%; otherwise, the original plan will continue. The study aims to determine how often plan adjustments are needed and to identify which disease sites are most likely to experience significant anatomical changes during treatment.\n\nPrimary Objective:\n\n* Define the frequency of replanning necessary to ensure tumor coverage never falls below 95% (or 5% drop) of the prescribed daily dose in participants with intact (gross) tumors to keep the tumor control optimal throughout the multi-week treatment regimen.\n* Define the frequency of replanning necessary to ensure organs-at-risk (critical organs) do not deviate by more than 10% of the initially approved dose constraints to keep the normal tissue complication minimal throughout the multi-week treatment regimen.\n\nSecondary Objectives\n\n* Establish a cone beam CT (CBCT)-based framework for quantifying body surface changes throughout the treatment course. This goal will be achieved by developing a novel algorithm that detects and tracks external anatomical variations longitudinally, without requiring CBCT image enhancement, enabling precise assessment of daily participant setup consistency and anatomical stability.\n* Overcome daily CBCT quality limitations by generating synthetic CT images that accurately represent daily anatomy and support proton dose recalculation or verification planning. This goal will be achieved by developing a hybrid pipeline that integrates deep learning models with the deformable image registration algorithm, trained and validated on disease site-specific data. This will enable precise dose mapping and tissue density estimation, directly supporting adaptive planning decisions without the need of diagnostic- quality CT images.",[24,25,26,27,28,29,30],"Pediatric Solid Tumors","Rhabdomyosarcoma","Ewing Sarcoma","Osteosarcoma","Hodgkin Lymphoma","Bone Tumor","Soft Tissue Sarcoma","NOT_YET_RECRUITING","2026-06-30",{"date":34,"type":35},"2026-07-02","ACTUAL",{"date":37,"type":18},"2026-08",{"date":39,"type":18},"2031-08",{"name":41,"class":42},"St. Jude Children's Research Hospital","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":15,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":19,"phases":55,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":43},"100551365","the-effect-of-acute-normovolemic-hemodilution-in-bone-tumor-surgery-100551365","NCT06459141","The Effect of Acute Normovolemic Hemodilution in Bone Tumor Surgery","The Effect of Acute Normovolemic Hemodilution on Intraoperative Allogeneic Transfusion in Bone Tumor Surgery: a Prospective, Randomized Controlled Trial","Inclusion Criteria:\n\n1. age 18 to 75 years;\n2. undergoing elective bone tumor resection surgery;\n3. preoperative hemoglobin ≥11 g\u002FdL;\n\nExclusion Criteria:\n\n1. using a tourniquet;\n2. palliative operation or minimally invasive surgery;\n3. BMI\\\u003C18.5 or \\>30Kg\u002Fm\\^2;\n4. international normalized ratio (INR) \\>1.5 or platelet count \\\u003C100 × 10\\^9\u002FL;\n5. cardiopulmonary insufficiency;\n6. hepatic and renal dysfunction;\n7. active infectious disease;\n8. allergy to succinyl gelatin;\n9. pregnancy;\n10. declined participation in the study or declined blood transfusion","18 Years","75 Years",{"count":54,"type":18},150,[21],"The prevention of intraoperative allogenetic blood transfusion has the potential to reduce complications, hospital stays, and long-term prognosis in patients undergoing bone cancer surgery. Data from previous studies suggest that the clinical efficacy of acute normovolemic hemodilution (ANH) has always been controversial. The HEAL trial will assess whether ANH will reduce the volume of intraoperative allogeneic red blood cell transfusion in patients undergoing bone cancer surgery.",[58,29,59,60],"Acute Normovolemic Hemodilution","Goal-Directed Fluid Therapy","Transfusion","RECRUITING","2026-06-22",{"date":64,"type":35},"2026-06-25",{"date":66,"type":35},"2024-06-07",{"date":68,"type":18},"2028-05",{"name":70,"class":42},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":15,"minAge":79,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":19,"phases":82,"briefSummary":83,"conditions":84,"keywords":87,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":101},"100617973","us-prospective-evaluation-of-epione-device-for-percutaneous-msk-procedures-100617973","NCT07325578","U.S. Prospective Evaluation of EPIONE Device for Percutaneous MSK Procedures","Evaluation of the Epione Robotic System for Image-guided Percutaneous MSK Procedures of the Pelvis and Spine in USA. A Prospective Study on Feasibility, Safety and Accuracy","EPIOS","Inclusion Criteria:\n\n* Patients ≥22 years old,\n* Patients approved for CT- or CBCT-guided MSK procedure in the pelvis or spine (except the cervical area) under general anesthesia,\n* Patients who have signed an IRB-approved informed consent form\n* Patients approved for coverage by their insurance for routine costs involved in this standard of care procedure\n* Inclusion criteria linked to the freehand procedure have been discussed and validated\n\nExclusion Criteria:\n\n* Patients with contraindication to undergo general anesthesia,\n* Patients unable to maintain appropriate breathing control,\n* Patients requiring CT- or CBCT-guided percutaneous procedure on target areas other than those indicated\n* Patients unable to fully understand all relevant aspects of the clinical study necessary for their decision to participate, or who could be manipulated or unduly influenced because of a compromised position, expectation of benefits or fear of retaliatory response,\n* Pregnant or breast-feeding women,\n* Patients subject to a legal protection measure,\n* Patients already participating in another conflicting interventional clinical study,\n* Patients for whom the scan field of view cannot contain the anatomy of interest, the overlaying skin surface, skin markers and the whole patient reference.\n* Patients having a coagulation abnormalities or bleeding disorder\n* Patients having an active infection on the day of intervention\n* Patients having a history of previous surgery resulting in an existing hardware precluding percutaneous approach\n* Exclusion criteria linked to the freehand procedure have been discussed and validated","22 Years",{"count":81,"type":18},60,[21],"The goal of this investigational device exemption is to evaluate the Epione assistance for introducer placement during percutaneous procedures in musculo-skeletic (MSK) structures of the pelvis and the spine in adults.\n\nThe main question is the determination of the rate of feasible procedures assisted by the Epione device\n\nParticipants will undergo their procedure(s) as planned by their physician. If they accept to participate to the study, the differences with standard of care will be:\n\n* The use of the Epione device to place the introducer(s), instead of freehand placement if they do not participate\n* Additional CT or CBCT scans during the procedure.",[29,85,86],"Osteoporosis","Traumatic Fracture",[88,89,90],"percutaneous procedure","robot assistance","bone procedure","2026-06-03",{"date":93,"type":35},"2026-06-04",{"date":95,"type":35},"2026-04-28",{"date":97,"type":18},"2026-10",{"name":99,"class":100},"Precision IO Group","INDUSTRY",3,{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":15,"minAge":51,"maxAge":109,"enrollmentInfo":110,"targetDuration":4,"studyType":111,"phases":4,"briefSummary":112,"conditions":113,"keywords":115,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":43},"100553470","proximal-femur-reconstruction-following-resection-of-primary-bone-tumors-analysis-of-the-clinical-and-radiographic-results-100553470","NCT06486506","Proximal Femur Reconstruction Following Resection of Primary Bone Tumors: Analysis of the Clinical and Radiographic Results","ProFemuRe","Inclusion Criteria:\n\n* Male and female patients surgically treated with an oncological reconstruction of the proximal femur at Rizzoli Orthopaedic Institute between 01\u002F01\u002F1991 and 31\u002F12\u002F2023\n* Age: 18-90 years old (at the time of primary surgery)\n* Diagnosis of bone sarcoma\n* Patients with available clinical and imaging data\n\nExclusion Criteria:\n\n* At least one inclusion criterion not met","90 Years",{"count":54,"type":18},"OBSERVATIONAL","From the archives of the Rizzoli institute all the patients (approximately 150 patients) undergoing oncological reconstruction of proximal femur from 01\u002F01\u002F1991 to 31\u002F12\u002F2023.\n\nA review will be made from the medical records, radiological imaging, and histological data of these patients",[29,114],"Bone Cancer",[116,117,118],"Proximal Femur Reconstruction","primary bone tumors","imaging","2026-05-21",{"date":121,"type":35},"2026-05-26",{"date":123,"type":35},"2024-04-29",{"date":125,"type":18},"2026-12-31",{"name":127,"class":42},"Costantino Errani",{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":15,"minAge":136,"maxAge":109,"enrollmentInfo":137,"targetDuration":4,"studyType":111,"phases":4,"briefSummary":139,"conditions":140,"keywords":142,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":152,"locationsCount":43},"100499162","adherence-to-a-personalized-home-exercise-program-in-patients-with-bone-tumor-undergoing-lower-extremity-salvage-surgery-100499162","NCT05779670","Adherence to a Personalized Home Exercise Program in Patients With Bone Tumor Undergoing Lower Extremity Salvage Surgery","Treatment Adherence to a Personalized Home Exercise Program in Patients With Bone Cancer Undergoing Lower Extremity Resection and Reconstruction","ADER","Inclusion Criteria:\n\n* patients aged 12 years with bone tumor undergoing surgery (resection and reconstruction of the lower limb) and in adjuvant treatment\n* patients under physiotherapy treatment\n\nExclusion Criteria:\n\n* patients with difficulties in understanding the Italian language\n* patients not using digital services","12 Years",{"count":138,"type":18},50,"The objective of this study is to describe adherence to a personalised home exercise program in patients undergoing resection and reconstruction of lower limb for bone tumor and neoadjuvant chemotherapy treatment in the first six months after surgery intervention and investigate possible prognostic factors.",[27,26,141,29],"Chondrosarcoma",[143,144,145],"rehabilitation","home based exercise","bone tumor","2026-02-02",{"date":148,"type":35},"2026-02-03",{"date":150,"type":35},"2023-01-01",{"date":125,"type":18},{"name":153,"class":42},"Istituto Ortopedico Rizzoli",{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":160,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":15,"minAge":162,"maxAge":163,"enrollmentInfo":164,"targetDuration":4,"studyType":111,"phases":4,"briefSummary":165,"conditions":166,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":4},"100618853","evaluation-of-tumor-resection-and-reconstruction-with-prosthetic-implants-100618853","NCT07337018","Evaluation of Tumor Resection and Reconstruction With Prosthetic Implants","Valutazione Resezioni Oncologiche e Ricostruzione Con Utilizzo di Impianti Protesici in Chirurgia Oncologica Ortopedica (Evaluation of Oncologic Resections and Reconstruction Using Prosthetic Implants in Orthopedic Oncologic Surgery)","RERIO","Inclusion Criteria:\n\n* Age between 30 and 70 years;\n\nDiagnosis of primary malignant or locally aggressive benign bone tumors, or secondary bone lesions with a primary diagnosis of breast, lung, prostate, kidney, or thyroid cancer;\n\nExtensive bone loss precluding the use of currently available prostheses or standard surgical techniques;\n\nUse of modular or custom-made prostheses produced with 3D-printing technology; minimum follow-up of 12 months;\n\n(For patients in the retrospective phase) completion of evaluation questionnaires during outpatient follow-ups;\n\nObtaining Informed Consent, except for deceased patients enrolled in the retrospective phase of the study.\n\nExclusion Criteria:\n\nPatients with disease spread to other bone segments;\n\nAge \\\u003C30 years or \\>70 years;\n\nPatients who have undergone previous surgical procedures on the involved segment;\n\nFollow-up of less than 1 year;\n\nIncomplete clinical or radiological data sets;\n\nInability to obtain Informed Consent, except for deceased patients enrolled in the retrospective phase of the study","30 Years","70 Years",{"count":17,"type":18},"Bone can be the site of primary malignant tumors or, more commonly, secondary lesions. The most frequent primary tumors are osteosarcoma, chondrosarcoma, and Ewing sarcoma, whereas the malignancies that most commonly metastasize to bone include breast, prostate, lung, kidney, and thyroid cancers.\n\nFor the treatment of these conditions-and, in some cases, for locally aggressive benign diseases-a surgical approach is often required, which may result in substantial bone loss. Most commercially available prostheses commonly used in orthopedic surgery are not always suitable, either because of the anatomical location of the procedure or the type of resection planned, and thus the extent of the bone defect to be reconstructed. Therefore, specific prosthetic implants designed for oncologic surgery are required.\n\nFor this reason, modular prostheses have been developed, allowing reconstruction of bone defects of varying sizes across different anatomical districts. In recent years, the development and use of 3D-printing technology for producing custom-made prostheses has also increased, with the aim of reconstructing bone defects in areas that are difficult to treat and achieving an accurate reproduction of the patient's anatomy. This technology enables reconstruction in a wide range of skeletal sites. Additionally, it allows for preoperative planning on printed anatomical models and opens the possibility of integrating materials with adjuvant-related properties into the prosthetic design, such as photothermal therapy or antimicrobial features.\n\nAlthough numerous studies on this topic are available in the literature, they frequently involve small patient cohorts. There is therefore a need to expand case series with longer follow-ups to better assess the reliability and effectiveness of these treatment strategies in the development of reconstructive orthopedic oncologic surgery.",[29],"2026-01-07",{"date":169,"type":35},"2026-01-13",{"date":171,"type":18},"2026-01-01",{"date":173,"type":18},"2028-11-30",{"name":175,"class":42},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":180,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":15,"minAge":51,"maxAge":52,"enrollmentInfo":181,"targetDuration":4,"studyType":19,"phases":183,"briefSummary":184,"conditions":185,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":190,"leadSponsor":192,"locationsCount":43},"100583835","a-substudy-of-the-effect-of-acute-normovolemic-hemodilution-in-bone-tumor-surgery-100583835","NCT06881498","A Substudy of the Effect of Acute Normovolemic Hemodilution in Bone Tumor Surgery",{"count":182,"type":18},32,[21],"The prevention of perioperative anemia has the potential to reduce complications, hospital stays, and long-term prognosis in patients undergoing bone tumor surgery. Data from previous studies suggest that the clinical efficacy of acute normovolemic hemodilution (ANH) has always been controversial, and intraoperative fluid administration strategy is an important confounding factor. The HEAL trial will assess whether ANH will improve postoperative hemoglobin levels when applying goal-directed fluid therapy in patients undergoing bone tumor surgery.",[29,58,59],"2025-04-13",{"date":188,"type":35},"2025-04-15",{"date":66,"type":35},{"date":191,"type":18},"2026-05",{"name":70,"class":42},{"id":194,"slug":195,"hasResults":11,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":4,"eligibilityCriteria":199,"healthyVolunteers":11,"sex":15,"minAge":200,"maxAge":52,"enrollmentInfo":201,"targetDuration":4,"studyType":19,"phases":202,"briefSummary":204,"conditions":205,"keywords":207,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":43},"100529246","early-phase-1-a-clinical-study-on-oncolytic-virus-injection-r130-for-the-treatment-of-advanced-bone-and-soft-tissue-tumors-100529246","NCT06171282","A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Bone and Soft Tissue Tumors","A Clinical Safety and Efficacy Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Bone and Soft Tissue Tumors","Inclusion Criteria:\n\n1. Age 16 to 75 years, diagnosed with soft tissue sarcoma or bone neoplasms clearly by histology and\u002For cytology.\n2. Failure of standard treatment or patient unwillingness to receive other antitumor therapy.\n3. No absolute or relative centasis contraindiction.\n4. Subjects with ECoG score of 0-2.\n5. Expected survival of 3 months or more.\n6. Have at least one measurable lesion (according to RECIST 1.1 criteria) that is amenable to intratumoral drug delivery.\n7. Subjects must have appropriate organ function, and laboratory tests during the screening period must meet the following requirements: a) absolute neutrophil count (ANC) ≥ 1.5 × 109\u002FL, platelets (PLT) ≥ 80 × 109\u002FL, and hemoglobin (Hb) ≥ 85 g\u002FL; b) serum creatinine (Cr) and blood urea nitrogen (BUN) within 1.5 times the upper limit of normal values; c) serum total bilirubin (TBIL) ≤ 2 times the upper limit of normal values; d) glutamic aminotransferase (ALT) and glutamic oxalacetic aminotransferase (AST) ≤ 2.5 times the upper limit of normal values; subjects with liver metastases do not exceed 5 times the upper limit of normal values; e) activated partial thromboplastin time (APTT), prothrombin time (PT) within 1.5 times the upper limit of normal values.\n8. Any treatment for malignancy, including radiotherapy, chemotherapy and biological agents, must be discontinued 28 days prior to R130 treatment.\n9. Eligible patients of childbearing potential must agree to use a reliable method of contraception (hormonal or barrier method or abstinence) with their partner for the duration of the trial and for at least 180 days after the last dose; female patients of childbearing potential must have a negative urine pregnancy test within 7 days prior to enrollment.\n10. Subjects voluntarily sign an informed consent form and are in good compliance.\n\nExclusion Criteria:\n\n1. Have had any serious adverse reactions associated with immunotherapy and have not recovered to CTCAE 5.0 grade rating 0 or 1 level of toxicity after previous antineoplastic therapy.\n2. Subjects with any severe and\u002For uncontrolled disease, including: a) poorly controlled hypertension (systolic blood pressure ≥ 150 mmHg or diastolic blood pressure ≥ 100 mmHg); b) suffering from class I or higher myocardial ischemia or myocardial infarction, arrhythmia (QTc ≥ 470 ms and ≥ grade 2 congestive heart failure (New York Heart Association (NYHA) classification); c) active or uncontrolled severe infection (≥ CTCAE grade 2 infection); d) Patients with previous organ transplantation, bone marrow transplantation (hematopoietic stem cell transplantation) and severe immune deficiency; e) Urine routine suggesting urine protein ≥++ and confirmed 24-hour urine protein quantification \\> 1.0 g.\n3. Patients with past history of type I diabetes mellitus or HIV.\n4. Severe abnormalities in thyroid and cortisol testing; active, known or suspected autoimmune disease requiring systemic therapy.\n5. Patients with active tuberculosis and a strong positive OT test.\n6. Patients with active bleeding or severe coagulation dysfunction.\n7. Have had antitumor therapy, including endocrine, chemotherapy, radiotherapy, targeted therapy, immunotherapy and antitumor herbal therapy, 4 weeks prior to the first dose.\n8. Current active hepatitis B, active hepatitis C, immunodeficiency virus or other active infection of clinical significance.\n9. Patients who have undergone surgery of grade 3 or higher or whose surgical wounds have not healed within 4 weeks prior to enrollment.\n10. Pregnant, lactating and planning to have children within six months.\n11. Subjects who, in the judgment of the investigator, are unsuitable for participation in this trial for any reason.","16 Years",{"count":5,"type":18},[203],"EARLY_PHASE1","9 participants are expected to be enrolled for this open，Single-armed clinical trial to evaluate the safety and efficacy of the recombinant herpes simplex virus Ⅰ, R130 in patients with advanced bone and soft tissue tumors.",[27,206,30,29],"Sarcoma",[208,209,210],"Oncolytic virus","Herpes simplex virus type 1","Immunotherapy","2023-12-06",{"date":213,"type":35},"2023-12-14",{"date":215,"type":35},"2023-07-12",{"date":217,"type":18},"2026-07-12",{"name":219,"class":100},"Shanghai Yunying Medical Technology",{"id":221,"slug":222,"hasResults":11,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":226,"eligibilityCriteria":227,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":228,"targetDuration":230,"studyType":111,"phases":4,"briefSummary":231,"conditions":232,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":264,"locationsCount":4},"100478829","registry-for-children-adolescents-and-adults-with-osteosarcoma-and-biologically-related-bone-sarcomas-100478829","NCT05515068","Registry For Children, Adolescents And Adults With Osteosarcoma And Biologically Related Bone Sarcomas","Registry For Children, Adolescents And Adults With Osteosarcoma And Biologically Related Bone Sarcomas (COSS-Registry)","COSS-Registry","Inclusion Criteria:\n\n* high-grade osteosarcoma (conventional and non-conventional)\n* parosteal, periosteal or extraosseous osteosarcoma\n* low grade central osteosarcoma\n* (osseous) Undifferentiated pleomorphic sarcoma (UPS)\n* (osseous) leiomyosarcoma\n* (osseous) dedifferentiated chondrosarcoma\n* (osseous) mesenchymal chondrosarcoma\n* (osseous) fibrosarcoma\n* (osseous) angiosarcoma\n* informed consent\n\nExclusion Criteria:\n\n* no informed consent",{"count":229,"type":18},1000,"20 Years","The Registry For Children, Adolescents And Adults With Osteosarcoma And Biologically Related Bone Sarcomas (COSS-Registry) is a non-interventional, multicentric, international, clinical and epidemiologic patient registry. The COSS-Registry collects key data on osteosarcomas or biologically related bone sarcomas. With that data collection we want to gain new scientific insights and results about this tumor disease, prognosis, surveillance and long-term effects.\n\nBesides the data collection we would also like to foster the collection of biomaterial (tumor specimen and blood samples) for scientific research.\n\nThe stored material will be used to perform cell and molecular biological analyses to identify the causes of osteosarcoma, the prognosis and possible new treatment options.\n\nAs a starting point the donated biomaterial of registered patients will be analyzed firstly for the presence of a tumor predisposition by germline mutations.\n\nIn case of detected genetic variations that are related to the tumor disease and which may affect the patient's health and follow-up care (because of the potentially increased risk of developing other malignant tumors), affected patients will be informed and referred to genetic counseling.\n\nRegistry patients will be asked at the time of diagnosis if they wish to be informed about germline variants detected as part of the study procedures.",[27,29,233,234,235,236,237,238,239,240,241,242,243,244,245,246,247,248,249,250,251,252,253,254,255,256],"Bone Sarcoma","High Grade Sarcoma","Osteoblastic Osteosarcoma","Chondroblastic Osteosarcoma","Fibroblastic Osteosarcoma","Conventional Osteosarcoma","Conventional Central Osteosarcoma of Bone","Low Grade Central Osteosarcoma","Osseous Sarcoma","Osseous Tumor","Small Cell Osteosarcoma","Telangiectatic Osteosarcoma","Undifferentiated Pleomorphic Sarcoma","Parosteal Osteosarcoma","Periosteal Osteosarcoma","Extraskeletal Osteosarcoma","Recurrent Osteosarcoma","High Grade Surface Osteosarcoma","Osseous Angiosarcoma","Osseous Fibrosarcoma","Osseous Leiomyosarcoma","Osseous Dedifferentiated Chondrosarcoma","Osseous Mesenchymal Chondrosarcoma","Clear Cell Osteosarcoma","2022-08-24",{"date":259,"type":35},"2022-08-25",{"date":261,"type":18},"2022-09",{"date":263,"type":18},"2032-03",{"name":265,"class":42},"Klinikum Stuttgart"]